These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 3089539)

  • 41. The interaction of 1-alkyl-4,4-diphenylpiperidines with the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine receptor binding site.
    Russ H; Pindur U; Przuntek H
    J Neural Transm; 1986; 65(3-4):157-66. PubMed ID: 3011983
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Toxicity of MPTP and structural analogs in clonal cell lines of neuronal origin expressing B type monoamine oxidase activity.
    Buckman TD
    Mol Chem Neuropathol; 1991 Oct; 15(2):87-102. PubMed ID: 1776993
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Development of fluorinated 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine analogs with potent nigrostriatal toxicity for potential use in positron emission tomography studies.
    Harik SI; Riachi NJ; Hritz MA; Berridge MS; Sayre LM
    J Pharmacol Exp Ther; 1993 Aug; 266(2):790-5. PubMed ID: 8355208
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Oxidation of analogs of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by monoamine oxidases A and B and the inhibition of monoamine oxidases by the oxidation products.
    Youngster SK; McKeown KA; Jin YZ; Ramsay RR; Heikkila RE; Singer TP
    J Neurochem; 1989 Dec; 53(6):1837-42. PubMed ID: 2809594
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity.
    Javitch JA; D'Amato RJ; Strittmatter SM; Snyder SH
    Proc Natl Acad Sci U S A; 1985 Apr; 82(7):2173-7. PubMed ID: 3872460
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Histochemistry of MPTP oxidation in the rat brain: sites of synthesis of the parkinsonism-inducing toxin MPP+.
    Nakamura S; Vincent SR
    Neurosci Lett; 1986 Apr; 65(3):321-5. PubMed ID: 3487052
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Correlation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity with blood-brain barrier monoamine oxidase activity.
    Kalaria RN; Mitchell MJ; Harik SI
    Proc Natl Acad Sci U S A; 1987 May; 84(10):3521-5. PubMed ID: 3495000
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Inhibition of the bioactivation of the neurotoxin MPTP by antioxidants, redox agents and monoamine oxidase inhibitors.
    Herraiz T; Guillén H
    Food Chem Toxicol; 2011 Aug; 49(8):1773-81. PubMed ID: 21554916
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Selegiline and the prophylaxis of Parkinson's disease.
    Sandler M; Willoughby J; Glover V; Gibb C
    J Neural Transm Suppl; 1987; 25():35-43. PubMed ID: 3123604
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Neuroprotective rather than neurorescue or neurorestorative effect of selegiline against MPTP-induced dopaminergic toxicity.
    Wu WR; Zhu XZ; Guan HJ; Wang RG; Ji XQ
    Zhongguo Yao Li Xue Bao; 1999 Feb; 20(2):146-50. PubMed ID: 10437162
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pargyline prevents MPTP-induced parkinsonism in primates.
    Langston JW; Irwin I; Langston EB; Forno LS
    Science; 1984 Sep; 225(4669):1480-2. PubMed ID: 6332378
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prevention of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic toxicity in mice by MDL 72145, a selective inhibitor of MAO-B.
    Kindt MV; Heikkila RE
    Life Sci; 1986 Apr; 38(16):1459-62. PubMed ID: 3084895
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prevention of dopaminergic toxicity of MPTP in mice by phenylethylamine, a specific substrate of type B monoamine oxidase.
    Melamed E; Youdim MB
    Br J Pharmacol; 1985 Nov; 86(3):529-31. PubMed ID: 3877535
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A reactive metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine is formed in rat brain in vitro by type B monoamine oxidase.
    Corsini GU; Pintus S; Bocchetta A; Piccardi MP; Del Zompo M
    J Pharmacol Exp Ther; 1986 Aug; 238(2):648-52. PubMed ID: 3488394
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Potent neurotoxic fluorinated 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine analogs as potential probes in models of Parkinson disease.
    Riachi NJ; Arora PK; Sayre LM; Harik SI
    J Neurochem; 1988 Apr; 50(4):1319-21. PubMed ID: 3258018
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Metabolism of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in a rat pheochromocytoma cell line, PC12h.
    Naoi M; Takahashi T; Nagatsu T
    Life Sci; 1987 Dec; 41(24):2655-61. PubMed ID: 3121966
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Nitroindazole compounds inhibit the oxidative activation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxin to neurotoxic pyridinium cations by human monoamine oxidase (MAO).
    Herraiz T; Arán VJ; Guillén H
    Free Radic Res; 2009 Oct; 43(10):975-84. PubMed ID: 19669997
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Potential bioactivation pathways for the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
    Castagnoli N; Chiba K; Trevor AJ
    Life Sci; 1985 Jan; 36(3):225-30. PubMed ID: 3871243
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Processing of MPTP by monoamine oxidases: implications for molecular toxicology.
    Trevor AJ; Singer TP; Ramsay RR; Castagnoli N
    J Neural Transm Suppl; 1987; 23():73-89. PubMed ID: 3295117
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immunity of fetal mice to prenatal administration of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Melamed E; Rosenthal J; Youdim MB
    J Neurochem; 1990 Oct; 55(4):1427-31. PubMed ID: 2398363
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.